Afeditab Cr

Anal sphincter hypertonia, Proctalgia, Altitude Sickness + 12 more

Treatment

3 FDA approvals

20 Active Studies for Afeditab Cr

What is Afeditab Cr

Nifedipine

The Generic name of this drug

Treatment Summary

Nifedipine is a medication used to relax and widen the blood vessels, allowing the heart to pump more efficiently. It belongs to a class of drugs called calcium channel blockers and was first developed by Bayer in 1972. Nifedipine was approved by the FDA in 1981 and is similar to other drugs like nicardipine and amlodipine, which are newer generations of dihydropyridines with slower onset and longer duration times.

Procardia

is the brand name

image of different drug pills on a surface

Afeditab Cr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Procardia

Nifedipine

1981

355

Approved as Treatment by the FDA

Nifedipine, otherwise called Procardia, is approved by the FDA for 3 uses like Angina, Stable and Failed conventional therapy .

Angina, Stable

Helps manage Chronic Stable Angina Pectoris

Failed conventional therapy

Helps manage Failed conventional therapy

Vasospastic Angina

Helps manage Vasospastic Angina

Effectiveness

How Afeditab Cr Affects Patients

Nifedipine is a drug that helps lower blood pressure and increase oxygen levels to the heart. It usually needs to be taken three times a day in doses of 10-120mg. Patients should be warned of the potential side effects, such as dangerously low blood pressure, chest pain, and heart attack.

How Afeditab Cr works in the body

Nifedipine decreases the amount of calcium that can enter cells in your veins and arteries, making them wider and reducing blood pressure. It also increases the amount of oxygen getting to the heart, relieving the chest pain of angina.

When to interrupt dosage

The prescribed dosage of Afeditab Cr is contingent upon the diagnosed condition, such as Achalasia, Ureteral Calculus and Hypertensive disease. The amount of dosage fluctuates, according to the form of administration (e.g. Tablet, film coated, extended release or Capsule) presented in the table below.

Condition

Dosage

Administration

Ureteral Calculi

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Angina, Stable

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Fissure in Ano

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Vasospastic Angina

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Failed conventional therapy

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Proctalgia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Pulmonary Edema

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Altitude Sickness

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Raynaud Disease

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Hypertensive disease

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Hypertensive Emergency

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Anal sphincter hypertonia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Obstetric Labor, Premature

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Esophageal Achalasia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Pulmonary Hypertension

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Warnings

Afeditab Cr has one contraindication, so it should not be taken concomitantly with any of the conditions indicated in the following table.

Afeditab Cr Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nifedipine may interact with Pulse Frequency

There are 20 known major drug interactions with Afeditab Cr.

Common Afeditab Cr Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Nifedipine.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Nifedipine.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Artemether.

Afeditab Cr Toxicity & Overdose Risk

The lowest toxic dose of the drug in rats has been found to be 1022mg/kg and in mice is 202mg/kg. Those who overdose on the drug may experience low blood pressure, abnormal heart rhythms, and a faster than normal heart rate. Treatment includes monitoring vital signs, raising the patient's extremities, and administering fluids, vasopressors, and calcium infusions.

image of a doctor in a lab doing drug, clinical research

Afeditab Cr Novel Uses: Which Conditions Have a Clinical Trial Featuring Afeditab Cr?

Currently, 101 active clinical trials are investigating the possible benefits of Afeditab Cr in Achalasia, Hypertensive Emergency and Anal Fissure management.

Condition

Clinical Trials

Trial Phases

Obstetric Labor, Premature

2 Actively Recruiting

Not Applicable

Pulmonary Edema

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Angina, Stable

0 Actively Recruiting

Esophageal Achalasia

0 Actively Recruiting

Altitude Sickness

0 Actively Recruiting

Raynaud Disease

1 Actively Recruiting

Phase 4

Pulmonary Hypertension

31 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1

Proctalgia

0 Actively Recruiting

Hypertensive Emergency

1 Actively Recruiting

Phase 4

Fissure in Ano

0 Actively Recruiting

Vasospastic Angina

1 Actively Recruiting

Phase 2, Phase 3

Anal sphincter hypertonia

0 Actively Recruiting

Ureteral Calculi

0 Actively Recruiting

Failed conventional therapy

0 Actively Recruiting

Afeditab Cr Reviews: What are patients saying about Afeditab Cr?

5

Patient Review

1/30/2011

Afeditab Cr for High Blood Pressure

At first, this medication really helped me. However, now I find that it gives me headaches. That said, my blood pressure has lowered since taking this pill so overall I'm happy with it.

5

Patient Review

10/9/2010

Afeditab Cr for High Blood Pressure

This treatment is excellent for lowering blood pressure, but a side effect I've noticed is that my gums keep swelling.

4.3

Patient Review

8/9/2009

Afeditab Cr for High Blood Pressure

I was on this medication for two weeks and saw a significant decrease in my blood pressure. I unfortunately had to stop taking it because the headaches it caused me were unbearable.

2

Patient Review

2/2/2009

Afeditab Cr for High Blood Pressure

Patient Q&A Section about afeditab cr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does CR tablet mean?

"Abbreviations that are commonly used by pharmaceutical companies to denote short- and long-acting medications include CR for “controlled release”, SR for “sustained release”, ER for “extended release”, and IR for “immediate release”."

Answered by AI

Is Afeditab the same as nifedipine?

"The tablets come in two different strengths, 30 mg or 60 mg. They are taken orally once per day."

Answered by AI

How does nifedipine work?

"Nifedipine is a calcium channel blocker that works by affecting the movement of calcium into the cells of the heart and blood vessels. By reducing the workload of the heart, nifedipine increases the supply of blood and oxygen to the heart while relaxing blood vessels."

Answered by AI

Should I take high blood pressure medication?

"If your blood pressure is high or you have other health problems that put you at risk for heart attack or stroke, your doctor mayrecommend medication to help lower your blood pressure."

Answered by AI

Clinical Trials for Afeditab Cr

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Image of UPMC Presybeterian in Pittsburgh, United States.

Telaglenastat for Pulmonary Hypertension

18 - 75
All Sexes
Pittsburgh, PA

The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is a progressive condition that affects the arteries in the lungs, specifically the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Telaglenastat is not currently approved by the Food and Drug Administration for the treatment of PH. However, the study investigators believe that Telaglenastat may help lower blood pressure in the lungs and improve both heart and lung function. It is important to note that the drug will not be available to participants once the study concludes.

Phase 1 & 2
Waitlist Available

UPMC Presybeterian

Michael Risbano, MD

Have you considered Afeditab Cr clinical trials?

We made a collection of clinical trials featuring Afeditab Cr, we think they might fit your search criteria.
Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL

Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.

Waitlist Available
Has No Placebo

University of Alabama at Birmingham

Pankaj Arora, MD, FAHA

Have you considered Afeditab Cr clinical trials?

We made a collection of clinical trials featuring Afeditab Cr, we think they might fit your search criteria.
Go to Trials
Image of UCSF Health St. Mary's Hospital in San Francisco, United States.

PF-07868489 for Pulmonary Hypertension

18+
All Sexes
San Francisco, CA

The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.

Phase 2
Recruiting

UCSF Health St. Mary's Hospital (+6 Sites)

Pfizer CT.gov Call Center

Pfizer

Have you considered Afeditab Cr clinical trials?

We made a collection of clinical trials featuring Afeditab Cr, we think they might fit your search criteria.
Go to Trials